Hepatocellular carcinoma non-resectable

This phase 2 trial tests whether a powerful mix of liver-directed chemotherapy, a targeted drug (lenvatinib), and an immunotherapy (cadonilimab) can shrink liver cancers that were too large or widespread to remove. The goal is to convert these inoperable tumors into ones that can…

This trial is testing whether adding hepatic arterial infusion chemotherapy (HAIC) to a combination of lenvatinib, sintilimab, and drug-eluting bead chemoembolization (DEB-TACE) can better control large liver cancers (over 7 cm) that have spread into the portal vein. About 320 pa…

This trial tests a treatment for people with liver cancer that cannot be removed by surgery. Tiny beads called BioPearl microspheres are loaded with the chemotherapy drug doxorubicin and injected into the blood vessels feeding the tumor. The beads block blood flow and release the…

This study tests whether adding a precise, high-dose radiation treatment (SBRT) after a standard procedure (TACE) can better control liver cancer in people whose tumors cannot be surgically removed. About 30 adults with early- or intermediate-stage liver cancer will receive the c…

This study tests a two-step treatment for people with advanced liver cancer that has spread into the main liver blood vessel (portal vein). First, patients receive targeted radiation (SIRT) to shrink the tumor from inside the liver. Then, they get two immunotherapy drugs (durvalu…

This phase 2 trial is testing whether adding proton radiotherapy to standard immunotherapy (atezolizumab and bevacizumab) can better control advanced liver cancer that cannot be removed by surgery. About 45 participants will receive the combination treatment. The study will measu…

This trial is testing whether a special PET/CT scan using 18F-fluorocholine, along with a liquid biopsy, can predict how well patients with inoperable liver cancer (hepatocellular carcinoma) will respond to immunotherapy. The study enrolls adults with this type of liver cancer wh…